FOXO3

FOXO3's Second Longevity Signal — A Distinct Regulatory Haplotype

FOXO3 is one of only two human genes — along with APOE — whose longevity associations have been consistently replicated
across multiple independent populations and ancestries. The first FOXO3 signal, rs2802292 | the well-characterized
HSF1-binding enhancer variant in intron 2, has been studied intensively
since 2008. But FOXO3's longevity architecture is more complex: rs1935949 tags a second, independent haplotype block
spanning 121 kilobases of FOXO3 intron 3 that independently contributes to centenarian enrichment through a
distinct regulatory mechanism.

Pawlikowska et al. 2009 | Association of common genetic variation in the insulin/IGF1 signaling pathway with human
longevity. Aging Cell. 2009 identified rs1935949 among longevity-associated
variants across three Caucasian cohorts — the Study of Osteoporotic Fractures, the Cardiovascular Health Study, and
Ashkenazi Jewish Centenarians — finding an overall OR of 1.24 (95% CI 1.09–1.41, p = 0.0014), with a stronger
association in women (OR = 1.35, 95% CI 1.15–1.57, adjusted p = 0.0093).

The Mechanism

rs1935949 sits in intron 3 of FOXO3, approximately 1.7 kilobase-pairs from an intron-exon boundary, and is in
strong linkage disequilibrium (r² = 0.96) with rs4946935 — the functionally characterized variant in the same
haplotype block. Flachsbart et al. 2017 | Identification and characterization of two functional variants in the
human longevity gene FOXO3. Nat Commun. 2017 demonstrated that the
longevity allele of rs4946935 creates an allele-dependent binding site for serum response factor (SRF) — a
transcription factor distinct from the heat shock factor 1 (HSF1) that binds the rs2802292 site. In luciferase
reporter assays, the longevity alleles at rs4946935 (and by proxy, rs1935949) show substantial enhancer activity
that is specifically reversed by IGF-1 treatment.

This IGF-1 reversibility is mechanistically significant. The insulin/IGF-1 signaling (IIS) pathway | the
PI3K-AKT cascade that phosphorylates and excludes FOXO3 from the nucleus
is the primary evolutionary brake on FOXO3 activity: high IGF-1 levels drive AKT activation, which phosphorylates
FOXO3 and traps it in the cytoplasm, preventing it from activating stress-response and longevity genes. The
longevity allele at rs1935949's haplotype creates an enhancer that is most active when IGF-1 is low — exactly
the dietary and metabolic condition under which FOXO3's protective functions matter most. This explains why the
variant was first identified in a study of IGF-1 signaling pathway genetics and why its effects are magnified
by caloric restriction and fasting contexts.

An eQTL database search confirms that the longevity alleles associated with the rs1935949/rs4946935 haplotype
block are associated with higher FOXO3 mRNA expression across multiple human tissues, consistent with the
enhancer model. The haplotype containing rs1935949 (haplotype block 1, alongside rs13217795, rs2764264, rs9400239,
and rs9486902, D'>0.86 spanning 121 kb) is structurally distinct | the haplotype blocks were identified
by LD analysis across 12 FOXO3 SNPs from the block containing
rs2802292, allowing independent additive effects on longevity.

The Evidence

Bao et al. 2014 | Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis.
Asian J Androl. 2014 pooled five independent studies encompassing
1,435 cases and 2,098 controls, finding significant overall longevity association (OR = 1.14, 95% CI 1.01–1.27).
Gender-stratified results suggested the overall association was not driven primarily by females in this cohort,
though the sex-specific picture is complex and differs across studies.

The largest replication effort comes from Bae et al. 2018 | Effects of FOXO3 polymorphisms on survival to extreme
longevity in four centenarian studies. J Gerontol A Biol Sci Med Sci. 2018,
which analyzed 2,072 cases and 6,194 controls across the Long Life Family Study, New England Centenarian Study,
Southern Italian Centenarian Study, and Longevity Genes Project. rs1935949 showed a meta-analysis beta of 0.18
(SE 0.044, p = 6.60×10⁻⁵), corresponding to approximately OR = 1.20 for extreme longevity (defined as surviving
to the oldest 1 percentile of the 1900 U.S. birth cohort — ≥96 years for males, ≥100 for females). Centenarian
enrichment of the protective G allele was observed in all four cohorts, though effect sizes varied.

Evidence is strongest in Caucasian populations. Studies in Chinese Han populations did not replicate
the rs1935949 association, consistent with population-specific LD patterns and potentially different
regulatory architectures across ancestries.

Practical Implications

The IGF-1-reversible nature of this haplotype's regulatory effect suggests a dietary angle that is more explicit
than for rs2802292. Dietary interventions that lower circulating IGF-1 — particularly plant-protein-predominant
diets and periodic fasting — reduce IGF-1-mediated suppression of FOXO3 at this enhancer. Caloric restriction
extending maximum lifespan in model organisms is mechanistically connected to reduced IIS signaling and consequent
FOXO3 activation; the rs1935949 haplotype may amplify this response.

The additive architecture of FOXO3 longevity signals is worth appreciating. Individuals who carry protective
alleles at both rs1935949 and rs2802292 benefit from independent contributions to FOXO3 expression through
distinct transcription factor binding sites (SRF at the rs4946935/rs1935949 haplotype; HSF1 at rs2802292).
The two mechanisms respond to different cellular stresses — nutrient status for the IGF-1-sensitive haplotype,
heat shock and oxidative stress for the HSF1 site — making them genuinely complementary.

Interactions

rs1935949 and rs2802292 are in different haplotype blocks across FOXO3 and have independent longevity effects.
Individuals carrying protective alleles at both loci likely experience additive longevity benefit through
distinct molecular mechanisms (SRF-mediated nutrient-sensing regulation vs. HSF1-mediated stress response
regulation). A compound action is worth considering for individuals carrying beneficial alleles at both rsids,
as the combined message — targeting both IGF-1 reduction and stress-response activation — is more specific
than either alone.

rs4946935 (r² = 0.96 with rs1935949) is the functional proxy variant for the enhancer mechanism; individuals
who have both in their genome data will likely have concordant results. rs13217795, also in haplotype block 1,
has been separately shown to regulate an alternative FOXO3 promoter (FOXO3-TR isoform expression), adding
another regulatory dimension to the same haplotype block.